Recommended Warning for Overthe-Counter. Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions
|
|
- Mary Stephens
- 2 years ago
- Views:
Transcription
1 Recommended Warning for Overthe-Counter Acetaminophen- Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document contact Emily Baker at U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) November 2014 Compliance
2 Recommended Warning for Overthe-Counter Acetaminophen- Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD Phone: or ; Fax: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) November 2014 Compliance
3 TABLE OF CONTENTS I. INTRODUCTION... 1 II. BACKGROUND... 1 III. DISCUSSION AND POLICY... 2 IV. EXAMPLE OTC DRUG FACTS LABEL WITH RECOMMENDED WARNING.. 3 i
4 Guidance for Industry 1 Recommended Warning for Over-the-Counter Acetaminophen- Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions This draft guidance, when finalized, will represent the Food and Drug Administration s (FDA s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance. I. INTRODUCTION FDA is informing manufacturers, members of the medical and scientific community, and other interested persons that at this time we do not intend to object to the marketing of single- and combination-ingredient, acetaminophen-containing, nonprescription (commonly referred to as over-the-counter (OTC)) drug products bearing a warning as described in this guidance (see section III, Discussion and Policy) alerting consumers that the use of acetaminophen may cause severe skin reactions. This guidance is intended to apply to single- and combination-ingredient acetaminophen-containing products marketed under the Tentative Final Monograph (TFM) for Internal Analgesic, Antipyretic, and Antirheumatic (IAAA) Drug Products for Over-the-Counter Human Use, published in the Federal Register (53 FR 46204, November 16, 1988). FDA s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance documents describe the Agency s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required. II. BACKGROUND Acetaminophen, included in many prescription and OTC products, is a common active ingredient indicated to treat pain and reduce fever. On August 1, 2013, FDA issued a Drug Safety Communication (DSC) informing the public that use of acetaminophen has been associated with 1 This guidance has been prepared by the Division of Nonprescription Regulation Development in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.
5 a risk of rare but serious skin reactions. 2 These skin reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis, can be fatal. The DSC explained that reddening of the skin, rash, blisters, and detachment of the upper surface of the skin can occur with the use of drug products that contain acetaminophen. These skin reactions can occur with the first-time use of acetaminophen or at any time while it is being taken. FDA advised health care professionals to be aware of this rare risk and consider acetaminophen, along with other drugs already known to have such an association, when assessing patients with potentially drug-induced skin reactions. FDA also advised that anyone who develops a skin rash or reaction while using acetaminophen or any other pain reliever/fever reducer should stop taking the drug and seek medical attention right away. Furthermore, the announcement advised that anyone who has experienced a serious skin reaction when taking acetaminophen in the past should not take the drug again and should contact their health care professional to discuss alternative pain relievers/fever reducers. In the announcement, FDA stated that it planned to require manufacturers of acetaminophencontaining prescription drug products to include a warning statement on the product labels to address the risk of serious skin reactions and that it would request the same warning be added by manufacturers of OTC acetaminophen-containing drug products marketed under an approved application. In the fall of 2013, FDA sent letters to manufacturers holding new drug applications (NDA) and abbreviated new drug applications (ANDA) requiring in some cases and requesting in others that the language recommended below be included on the labeling for all products (both prescription and OTC) containing acetaminophen marketed under NDAs and ANDAs. At this time, most of the requested labeling changes have been made by the relevant manufacturers. FDA also indicated that it planned to encourage manufacturers of acetaminophen-containing drug products marketed under the TFM to similarly add a warning about serious skin reactions to the product labels. III. DISCUSSION AND POLICY FDA recommends that manufacturers of all acetaminophen-containing OTC drug products marketed pursuant to the TFM for IAAA Drug Products (both single- and combinationingredient acetaminophen products) include language in labeling warning consumers that acetaminophen may cause severe skin reactions. At this time, FDA does not intend to object to the marketing of products containing the following warning language described below: Allergy alert: acetaminophen may cause severe skin reactions. Symptoms may include: [bullet] skin reddening [bullet] blisters [bullet] rash 2 FDA Drug Safety Communication: FDA warns of rare but serious skin reactions with the pain reliever/fever reducer acetaminophen. 2
6 If a skin reaction occurs, stop use and seek medical help right away. This guidance does not address alternative warning language that may otherwise misbrand the product. This recommended warning should appear under the Warnings heading section of the Drug Facts label under the subheading Allergy Alert and directly follow the liver warning (21 CFR ) on acetaminophen-containing drug products. FDA recommends that this warning be included on all packaging configurations. IV. EXAMPLE OTC DRUG FACTS LABEL WITH RECOMMENDED WARNING Drug Facts Active Ingredient (in each [insert dosage form]) Purpose Acetaminophen XXX mg....pain reliever/fever reducer Uses (Insert as described in an applicable OTC drug monograph or approved drug application.) Warnings Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take: more than [insert quantity and dosage form] in 24 hours, which is the maximum daily amount with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product Allergy alert: acetaminophen may cause severe skin reactions. Symptoms may include: skin reddening blisters rash If a skin reaction occurs, stop use and seek medical help right away. Do not use with any other drug containing acetaminophen (prescription or nonprescription). If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist. for more than 10 days for pain unless directed by a doctor for more than 3 days for fever unless directed by a doctor Ask a doctor before use if you have liver disease Ask a doctor or pharmacist before use if you are taking the blood thinning drug warfarin Stop using and ask a doctor if symptoms do not improve new symptoms occur pain or fever persists or gets worse If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of accidental overdose, get medical help or contact a Poison Control Center right away. Prompt medical attention is critical for adults as well as for children even if you do not notice any signs or symptoms. Directions (Insert as described in an applicable OTC drug monograph or approved drug application.) Other Information (Insert any additional information that is not included under the other subheadings but which is required or is made optional under an OTC drug monograph(s), other OTC drug regulation(s), approved drug 3
7 application, statute, or OTC drug guidance.) Contains Nonbinding Recommendations Inactive Ingredients (Insert a list of each inactive ingredient, using its established name.) Questions or Comments (Insert optional heading used to provide a telephone number of a source to answer questions about the drug product or to receive reports of adverse events associated with the use of the drug product.) 4
Guidance for Industry
Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,
Reprinted from FDA s website by Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Guidance And Antiasthmatic for Drug Industry Products for Over-the-Counter Labeling
Guidance for Industry
Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
Use of Electronic Health Record Data in Clinical Investigations
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Guidance for Industry DRAFT GUIDANCE
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information Guidance for Industry DRAFT GUIDANCE
Guidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide
Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide U.S. Department of Health and Human Services Center for Drug Evaluation and
Medical Device Data Systems, Medical Image Storage Devices, and Medical Image
4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-0798] Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices;
Guidance for Industry
Guidance for Industry Charging for Investigational Drugs Under an IND Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Content of Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Guidance for Industry
Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry Providing Regulatory Submissions in Electronic Format Standardized Study Data DRAFT GUIDANCE This guidance document is being
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA
Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics DRAFT GUIDANCE This guidance
Guidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products
Guidance for Industry Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products Small Entity Compliance Guide Written comments and suggestions may be
Guidance for Industry
Guidance for Industry Electronic Source Data in Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification
Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
Guidance for Industry Classifying Resubmissions in Response to Action Letters
Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
Charging for Investigational Drugs Under an Investigational New Drug Application--Questions
This document is scheduled to be published in the Federal Register on 06/03/2016 and available online at http://federalregister.gov/a/2016-13166, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Guidance for Industry DRAFT GUIDANCE This guidance document
Good Review Practice. October 2009 Labeling
Guidance for Industry and Review Staff Labeling for Human Prescription Drug and Biological Products Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information Good
Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO
This document is scheduled to be published in the Federal Register on 05/29/2014 and available online at http://federalregister.gov/a/2014-12349, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
Contains Nonbinding Recommendations. Document issued on October 20, 2006
Guidance for Industry and FDA Staff Exemption from Certain Reporting and Recordkeeping Requirements for Television Receivers and Computer Monitors with Cathode Ray Tubes Document issued on October 20,
Guidance for Industry Certification Process for Designated Medical Gases
Guidance for Industry Certification Process for Designated Medical Gases DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Guidance for Industry
Guidance for Industry Bar Code Label Requirements Questions and Answers (Question 12 Update) DRAFT GUIDANCE This guidance document is for comment purposes only. Submit comments on this draft guidance by
Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices
Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document
Guidance for Industry Bar Code Label Requirements Questions and Answers
Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation
Guidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry DRAFT GUIDANCE This guidance document is being
Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities
Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities FDA PUBLIC HEALTH ADVISORY Comments and suggestions regarding this document should be submitted within 90 days of publication in
Guidance for Industry
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Providing Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Gifts to the Food and Drug Administration: Evaluation and Acceptance: Draft Guidance for the
This document is scheduled to be published in the Federal Register on 06/29/2016 and available online at http://federalregister.gov/a/2016-15385, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Guidance for Industry
Guidance for Industry Submitting Debarment Certification Statements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Determination of Regulatory Review Period for Purposes of Patent Extension;
This document is scheduled to be published in the Federal Register on 12/15/2015 and available online at http://federalregister.gov/a/2015-31400, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors
This document is scheduled to be published in the Federal Register on 01/08/2016 and available online at http://federalregister.gov/a/2016-00149, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors
Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special
Contains Nonbinding Recommendations
Guidance for Industry and FDA Staff Laser Products Conformance with IEC 60825-1 and IEC 60601-2-22; Guidance for Industry and FDA Staff (Laser Notice No. 50) Document issued on June 24, 2007 This document
DRUG INTERACTIONS: WHAT YOU SHOULD KNOW. Council on Family Health
DRUG INTERACTIONS: WHAT YOU SHOULD KNOW Council on Family Health Drug Interactions There are more opportunities today than ever before to learn about your health and to take better care of yourself. It
Re: September 19,2002 meeting of the Nonprescription Drugs Advisory Committee to discuss safety issues related to the use of acetaminophen.
Pfizer Inc 201 Tabor Road Moms Plains, NJ 07950 Tel 973 385 2000 Fax 973 385 3761 Sandra Titus Advisors and Consultants Staff FDAKDER 5630 Fishers Lane Rockville, MD 20857 Re: September 19,2002 meeting
The Food and Drug Administration's Policy on Declaring Small Amounts of Nutrients and
This document is scheduled to be published in the Federal Register on 07/01/2016 and available online at http://federalregister.gov/a/2016-15477, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
CAREONE SINUS CONGESTION AND PAIN DAYTIME NIGHTTIMEacetaminophen,phenylephrine
CAREONE SINUS CONGESTION AND PAIN DAYTIME NIGHTTIMEacetaminophen,phenylephrine hcl, chlorpheniramine maleate American Sales Company Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however
Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation
This document is scheduled to be published in the Federal Register on 08/18/2015 and available online at http://federalregister.gov/a/2015-20317, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes
Guidance for Industry
Guidance for Industry Labeling OTC Human Drug Products Using a Column Format U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) December
Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
Guidance for Industry
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed
Guidance for Industry
Guidance for Industry Major, Minor, and Telephone Amendments to Abbreviated New Drug Applications Comments and suggestions regarding this document should be submitted within 90 days of publication in the
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Internet/Social Media Platforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document
Paracetamol apollo +9191 46 950 950. Paracetamol apollo +9191 46 950 950. Paracetamol
Paracetamol apollo +9191 46 950 950 Paracetamol apollo +9191 46 950 950 Paracetamol CAS Number : 103-90-2 Molecular Weight : 151.17 g/mol Molecular Formula : C8H9NO2 Systematic (IUPAC) : N-(4- hydroxyphenyl)ethanamide
Guidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Guidance. Useful Written Consumer Medication Information (CMI)
Guidance Useful Written Consumer Medication Information (CMI) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
Guidance for Industry Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act
Guidance for Industry Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act DRAFT GUIDANCE This guidance document is being distributed for comment purposes
Use of Standards in the Food and Drug Administration's Regulatory Oversight of Next
This document is scheduled to be published in the Federal Register on 07/08/2016 and available online at http://federalregister.gov/a/2016-16201, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Guidance for Industry
Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for
Dissemination of Patient-Specific Information from Devices by Device Manufacturers; Draft
This document is scheduled to be published in the Federal Register on 06/10/2016 and available online at http://federalregister.gov/a/2016-13787, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
FINAL GUIDANCE. For questions on the content of this guidance, contact Advisory Committee Oversight and Management Staff, at 301-796-8220.
Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers FINAL GUIDANCE Comments and suggestions
MEDICATION GUIDE SYLATRON (SY-LA-TRON) (Peginterferon alfa-2b)
MEDICATION GUIDE SYLATRON (SY-LA-TRON) (Peginterferon alfa-2b) Read this Medication Guide before you start taking SYLATRON, and each time you get a refill. There may be new information. This Medication
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
PAIN MEDICINES AND YOUR KIDNEYS
PAIN MEDICINES AND YOUR KIDNEYS What You Need to Know www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease
Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and
This document is scheduled to be published in the Federal Register on 11/18/2016 and available online at https://federalregister.gov/d/2016-27768, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
PHARMACIST DETACH HERE AND GIVE TO PATIENT
PHARMACIST DETACH HERE AND GIVE TO PATIENT MEDICATION GUIDE HORIZANT (ho-ri' zant) (gabapentin enacarbil) Extended-Release Tablets Read this Medication Guide before you start taking HORIZANT and each time
National Drug Code Directory
The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Drug Establishment Registration and Drug Listing U.S. Department of Health and Human Services Food and Drug Administration Office
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2006 Compliance
Guidance for Industry Prescription Drug Marketing Act Donation of Prescription Drug Samples to Free Clinics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.
MEDICATION GUIDE VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) Read this Medication Guide before you start receiving VIVITROL injections and each time you receive an injection.
WARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Peter A. Lankau President and CEO 100 Endo Boulevard Chadds Ford, PA
Remeron (mirtazapine)
Remeron (mirtazapine) FDA ALERT [07/2005] Suicidal Thoughts or Actions in Children and Adults Patients with depression or other mental illnesses often think about or attempt suicide. Closely watch anyone
Guidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Dear Health Care Provider Letters: Improving Communication of Important Safety Information U.S. Department of Health and Human Services Food and Drug Administration
UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES
UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the Matter of Dendy Foods, Inc. d/b/a Grocer s Pride ADMINISTRATIVE COMPLAINT FOR CIVIL MONEY
Document issued on: December 2, 2014. The draft of this document was issued on March 11, 2013. Contains Nonbinding Recommendations
Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex Guidance for Industry and Food and Drug Administration Staff Document
Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules
Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules Read this Medication Guide before you start taking EQUETRO and each time you get a refill. There may be new information. This
General Wellness: Policy for Low Risk Devices. Draft Guidance for Industry and Food and Drug Administration Staff
General Wellness: Policy for Low Risk Devices Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document
Safety Assessment for IND Safety Reporting Guidance for Industry
Safety Assessment for IND Safety Reporting Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
PRODUCT MONOGRAPH TARCEVA. erlotinib hydrochloride tablets. erlotinib 25, 100, 150 mg
PRODUCT MONOGRAPH Pr TARCEVA erlotinib hydrochloride tablets erlotinib 25, 100, 150 mg Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Hoffmann-La Roche Limited 7070 Mississauga Road
Guidance for Industry
Guidance for Industry Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages FINAL GUIDANCE U.S. Department of Health and Human Services Food
U.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
MEDICATION GUIDE. ARMODAFINIL (ar moe daf i nil) TABLETS C-IV
MEDICATION GUIDE ARMODAFINIL (ar moe daf i nil) TABLETS C-IV Read the Medication Guide that comes with armodafinil tablets before you start taking it and each time you get a refill. There may be new information.
Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets
Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Read this Patient Information carefully before you start taking VYTORIN and each time you get a refill. There may be new information.
Vibramycin Capsules Doxycycline hyclate capsules USP. Vibra-Tabs Film Coated Tablets Doxycycline hyclate tablets USP
32 READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Vibramycin Capsules Doxycycline hyclate capsules USP Vibra-Tabs Film Coated Tablets Doxycycline hyclate tablets USP
Medicines: Use Them Safely
What Are Medicines? What Are Drugs? Medicines: Use Them Safely When Jerry, age 71, came home from the drug store with his latest prescription, he placed all his pill bottles on the kitchen counter and
Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day
Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
Share the important information in this Medication Guide with members of your household.
MEDICATION GUIDE BUPRENORPHINE (BUE-pre-NOR-feen) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine sublingual tablets in a secure place away from children. Accidental use by a child is a medical
Guidance on adverse drug reactions
Guidance on adverse drug reactions Classification of adverse drug reactions Adverse drug reactions are frequently classified as type A and type B reactions. An extended version of this classification system
What is the most important information I should know about TREXIMET?
PATIENT IMPORTANT SAFETY INFORMATION What is the most important information I should know about TREXIMET? TREXIMET may increase your chance of a heart attack or stroke that can lead to death. TREXIMET